Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yifeng He

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
Research (Washington, D.C.)|January 28, 2026
A Deep Learning-Generated Mixed Tumor-Stroma Ratio for Prognostic Stratification and Multi-omics Profiling in Bladder CancerYifeng He, Jinbo Xie, Suquan Zhong, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|August 29, 2025
Graft PD-L1 as a predictive marker for rejection in PD-1 inhibitor therapy for recurrent liver tumors post-transplant: A prospective pilot trialYifeng He, Xiaowu Huang, Xiaoyong Huang, et al.
Hepatobiliary Surgery and Nutrition|September 2, 2025
Auxiliary liver transplantation using otherwise-discarded liver allograft combined with associating liver partition and portal vein ligation for staged hepatectomy for unresectable colorectal liver metastasesZheng Wang, Xiaowu Huang, Yinghong Shi, et al.
Signal Transduction and Targeted Therapy|August 20, 2025
First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 studyGuoming Shi, Xiaoyong Huang, Liang Ma, et al.
Hepatobiliary Surgery and Nutrition|October 21, 2022
Emergent hybrid-dual-graft liver transplantation: a life-saving strategy for a patient with inadequate living donor graft during the COVID-19 pandemicYongsheng Xiao, Xiaowu Huang, Yinghong Shi, et al.
The Lancet. Oncology|September 1, 2025
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 studyGuoming Shi, Xiaoyong Huang, Xiaowu Li, et al.
Clinical and Translational Medicine|March 7, 2023
p16<sup>INK4A</sup> flow cytometry of exfoliated cervical cells: Its role in quantitative pathology and clinical diagnosis of squamous intraepithelial lesionsYifeng He, Jun Shi, Hui Zhao, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Research (Washington, D.C.)|January 28, 2026
A Deep Learning-Generated Mixed Tumor-Stroma Ratio for Prognostic Stratification and Multi-omics Profiling in Bladder CancerYifeng He, Jinbo Xie, Suquan Zhong, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|August 29, 2025
Graft PD-L1 as a predictive marker for rejection in PD-1 inhibitor therapy for recurrent liver tumors post-transplant: A prospective pilot trialYifeng He, Xiaowu Huang, Xiaoyong Huang, et al.
Hepatobiliary Surgery and Nutrition|September 2, 2025
Auxiliary liver transplantation using otherwise-discarded liver allograft combined with associating liver partition and portal vein ligation for staged hepatectomy for unresectable colorectal liver metastasesZheng Wang, Xiaowu Huang, Yinghong Shi, et al.
Signal Transduction and Targeted Therapy|August 20, 2025
First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 studyGuoming Shi, Xiaoyong Huang, Liang Ma, et al.
Hepatobiliary Surgery and Nutrition|October 21, 2022
Emergent hybrid-dual-graft liver transplantation: a life-saving strategy for a patient with inadequate living donor graft during the COVID-19 pandemicYongsheng Xiao, Xiaowu Huang, Yinghong Shi, et al.
The Lancet. Oncology|September 1, 2025
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 studyGuoming Shi, Xiaoyong Huang, Xiaowu Li, et al.
Clinical and Translational Medicine|March 7, 2023
p16<sup>INK4A</sup> flow cytometry of exfoliated cervical cells: Its role in quantitative pathology and clinical diagnosis of squamous intraepithelial lesionsYifeng He, Jun Shi, Hui Zhao, et al.
Pageof 8